Cogent Biosciences · 3 months ago
Associate Director, Investigator-Initiated Trials & Expanded Access Programs
Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. The Associate Director, Investigator-Initiated Trials & Expanded Access Programs will play a critical role in ensuring continued access to investigational therapies prior to commercialization by leading the strategic development and operational oversight of Expanded Access Programs, Investigator-Sponsored Trials, and Rollover Protocols.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Design, implement, and manage expanded access strategies for Cogent products in compliance with global and country level regulatory requirements and internal SOPs
Lead cross-functional collaboration to enable timely decision-making, allocate resources efficiently, and maintain a seamless flow of information to internal and external partners
Oversee all aspects of the program, including timelines, budget, and resources
Collaborate with legal, pharmacovigilance, supply chain, and relevant cross functional teams to support access and distribution
Provide training and ongoing support to physicians on EAP program requirements, partnering with Medical Affairs on outreach/engagement strategy supporting access to patients
Contribute to the development of policies and strategies aligned with product lifecycle and global access objectives
Identify potential risks and develop mitigation strategies
In partnership with Medical Affairs, provide operational support for Investigator-sponsored Trials
Develop and implement processes to ensure consistent and efficient IST program execution, including tracking project timelines, managing risks, and coordinating with investigators
Develop, plan, and manage all aspects of clinical trial rollover programs, from feasibility and startup through closeout
Serve as the primary point of contact for and collaborate with internal and external stakeholders, including Medical Affairs, Regulatory Affairs, investigators, and Contract Research Organizations (CROs)
Ensure all program activities adhere to Good Clinical Practice (GCP), ICH guidelines, and all applicable national and international regulatory requirements
Develop and implement strategies to ensure efficient patient enrollment and retention within the extension program
Oversee the creation of patient-facing materials, tools, resources to improve continued trial engagement and retention
Qualification
Required
A bachelor's degree in life science, medicine, or a pharmacy-related field is required
8+ years of relevant experience in the pharmaceutical or biotech industry, with a minimum of 3 years of direct experience managing EAP and/or IST programs
Demonstrated experience in a leadership or senior role with responsibility for program strategy and oversight
Regulatory expertise: In-depth knowledge of GCP, FDA regulations governing Expanded Access (21 CFR Part 312), and ethical considerations for clinical research
Leadership and influence: Proven ability to lead cross-functional teams and influence internal and external stakeholders without direct authority
Communication: Excellent communication and interpersonal skills, with the ability to navigate sensitive topics with patients and external partners
Business acumen: Strong financial management skills for budget oversight and contract negotiation
Preferred
An advanced degree (e.g., MS, MPH, PharmD, PhD) is strongly preferred
Benefits
Competitive pay
Performance-based bonus
Stock options
Insurance coverage (health, dental, life, and disability)
Competitive time-off
A 401(k) plan
Commuter/parking benefits
Company
Cogent Biosciences
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
Funding
Current Stage
Public CompanyTotal Funding
$1.6BKey Investors
Commodore CapitalFairmount Funds ManagementSquare 1 Bank
2025-11-10Post Ipo Equity· $200M
2025-11-10Post Ipo Debt· $200M
2025-07-08Post Ipo Equity· $230M
Leadership Team
Recent News
2025-12-31
Company data provided by crunchbase